Decoding F508del Misfolding in Cystic Fibrosis

被引:10
|
作者
Wang, Xiaodong Robert [1 ]
Li, Chenglong [2 ]
机构
[1] Samford Univ, McWhorter Sch Pharm, Dept Pharmaceut, Social & Adm Sci, 800 Lakeshore Dr, Birmingham, AL 35229 USA
[2] Ohio State Univ, Coll Pharm, Div Med Chem & Pharmacognosy, Columbus, OH 43210 USA
来源
BIOMOLECULES | 2014年 / 4卷 / 02期
关键词
ABC transporter; CFTR; cystic fibrosis; drug discovery; F508del; molecular dynamics simulation; nucleotide-binding domain; protein conformation; protein folding; protein stability;
D O I
10.3390/biom4020498
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The functional deficiency of the cystic fibrosis transmembrane conductance regulator (CFTR), a plasma membrane chloride channel, leads to the development of cystic fibrosis. The deletion of a phenylalanine at residue 508 (F508del) is the most common cause of CFTR misfolding leading to the disease. The F508del misfolding originates in the first nucleotide-binding domain (NBD1), which induces a global conformational change in CFTR through NBD1's interactions with other domains. Such global misfolding produces a mutant chloride channel that is impaired in exocytic trafficking, peripheral stability, and channel gating. The nature and atomic details of F508del misfolding have been subject to extensive research during the past decade. Current data support a central role for NBD1 in F508del misfolding and rescue. Many cis-acting NBD1 second-site mutations rescue F508del misfolding in the context of full-length CFTR. While some of these mutations appear to specifically counteract the F508del-induced misfolding, others release certain inherent conformational constraints of the human wild-type CFTR. Several small-molecule correctors were recently found to act on key interdomain interfaces of F508del CFTR. Potential rational approaches have been proposed in an attempt to develop highly effective small molecule modulators that improve the cell surface functional expression of F508del CFTR.
引用
收藏
页码:498 / 509
页数:12
相关论文
共 50 条
  • [41] Manipulating proteostasis to repair the F508del-CFTR defect in cystic fibrosis
    Speranza Esposito
    Antonella Tosco
    Valeria R. Villella
    Valeria Raia
    Guido Kroemer
    Luigi Maiuri
    Molecular and Cellular Pediatrics, 3 (1)
  • [42] COMBINATION OF CORRECTORS AND POTENTIATORS FOR F508DEL CFTR
    Rowe, Steven M.
    Boyle, Michael P.
    PEDIATRIC PULMONOLOGY, 2011, : 180 - 181
  • [43] Breathing Easier: A Well-tolerated Corrector for F508del
    Nichols, David P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197 (02) : 152 - 154
  • [44] Cystic Fibrosis Patients with F508del/Minimal Function Genotype: Laboratory and Nutritional Evaluations after One Year of Elexacaftor/Tezacaftor/Ivacaftor Treatment
    Carnovale, Vincenzo
    Scialo, Filippo
    Gelzo, Monica
    Iacotucci, Paola
    Amato, Felice
    Zarrilli, Federica
    Celardo, Assunta
    Castaldo, Giuseppe
    Corso, Gaetano
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (23)
  • [45] Liver biochemical indexes and cholesterol metabolism in cystic fibrosis patients with F508del/CFTR variant genotype after elexacaftor/tezacaftor/ivacaftor treatment
    Castaldo, Alice
    Iacotucci, Paola
    Bagnasco, Sveva
    Fevola, Cristina
    Carnovale, Vincenzo
    Antonelli, Fabio
    Cernera, Gustavo
    Gelzo, Monica
    Terlizzi, Vito
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [46] Sheep models of F508del and G542X cystic fibrosis mutations show cellular responses to human therapeutics
    Viotti Perisse, Iuri
    Fan, Zhiqiang
    Van Wettere, Arnaud
    Liu, Ying
    Leir, Shih-Hsing
    Keim, Jacob
    Regouski, Misha
    Wilson, Michael D.
    Cholewa, Kelly M.
    Mansbach, Sara N.
    Kelley, Thomas J.
    Wang, Zhongde
    Harris, Ann
    White, Kenneth L.
    Polejaeva, Irina A.
    FASEB BIOADVANCES, 2021, 3 (10) : 841 - 854
  • [47] A prospective study to assess the impact of a novel CFTR therapy combination on body composition in patients with cystic fibrosis with F508del mutation
    Knott-Torcal, Carolina
    Sebastian-Valles, Fernando
    Moreno, Rosa Maria Giron
    Martin-Adan, Jose Carlos
    Jimenez-Diaz, Jessica
    Marazuela, Monica
    de la Blanca, Nuria Sanchez
    Fernandez-Contreras, Raul
    Arranz-Martin, Alfonso
    CLINICAL NUTRITION, 2023, 42 (12) : 2468 - 2474
  • [48] Impact of a Gap Junction Protein Alpha 4 Variant on Clinical Disease Phenotype in F508del Homozygous Patients With Cystic Fibrosis
    Horn, Tabea
    Ludwig, Michael
    Eickmeier, Olaf
    Neerinex, Anne H.
    van der Zee, Anke H.
    Smaczny, Christina
    Wagner, Thomas O. F.
    Schubert, Ralf
    Zielen, Stefan
    Majoor, Christof
    Bos, Lieuwe D.
    Schmitt-Grohe, Sabina
    FRONTIERS IN GENETICS, 2020, 11
  • [49] Elexacaftor/tezacaftor/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del
    Lopez, Andrea
    Daly, Conor
    Vega-Hernandez, Gabriela
    MacGregor, Gordon
    Rubin, Jaime L.
    JOURNAL OF CYSTIC FIBROSIS, 2023, 22 (04) : 607 - 614
  • [50] Targeting F508del-CFTR to develop rational new therapies for cystic fibrosis
    Zhi-wei Cai
    Jia Liu
    Hong-yu Li
    David N Sheppard
    Acta Pharmacologica Sinica, 2011, 32 : 693 - 701